BMC Public Health volume 23, Article number: 217 (2023 ) Cite this article
The ongoing benefits of coronavirus disease 2019 (COVID-19) nonpharmaceutical interventions (NPIs) for respiratory infectious diseases in China are still unclear. We aimed to explore the changes in seven respiratory infectious diseases before, during, and after COVID-19 in China from 2010 to 2021. Student Clickers Supplier
![Trends in respiratory diseases before and after the COVID-19 pandemic in China from 2010 to 2021 | BMC Public Health | Full Text](http://cdn.globalso.com/qomo-odm/71.jpg)
The monthly case numbers of seven respiratory infectious diseases were extracted to construct autoregressive integrated moving average (ARIMA) models. Eight indicators of NPIs were chosen from the COVID-19 Government Response Tracker system. The monthly case numbers of the respiratory diseases and the eight indicators were used to establish the Multivariable generalized linear model (GLM) to calculate the incidence rate ratios (IRRs).
Compared with the year 2019, the percentage changes in 2020 and 2021 were all below 100% ranging from 3.81 to 84.71%. Pertussis and Scarlet fever started to increase in 2021 compared with 2020, with a percentage change of 183.46 and 171.49%. The ARIMA model showed a good fit, and the predicted data fitted well with the actual data from 2010 to 2019, but the predicted data was bigger than the actual number in 2020 and 2021. All eight indicators could negatively affect the incidence of respiratory diseases. The seven respiratory diseases were significantly reduced during the COVID-19 pandemic in 2020 and 2021 compared with 2019, with significant estimated IRRs ranging from 0.06 to 0.85. In the GLM using data for the year 2020 and 2021, the IRRs were not significant after adjusting for the eight indicators in multivariate analysis.
Our study demonstrated the incidence of the seven respiratory diseases decreased rapidly during the COVID-19 pandemic in 2020 and 2021. At the end of 2021, we did see a rising trend for the seven respiratory diseases compared to the year 2020 when the NPIs relaxed in China, but the rising trend was not significant after adjusting for the NPIs indicators. Our study showed that NPIs have an effect on respiratory diseases, but Relaxation of NPIs might lead to the resurgence of respiratory diseases.
The first confirmed Chinese case of COVID-19 was reported in December 2019 [1, 2], causing the pandemic around the country. COVID-19 subsequently swept the world [3,4,5,6], and the number of COVID-19 cases has exceeded 528 million worldwide, involving more than 200 countries [7]. China has implemented public interventions to prevent the pandemic, including both pharmaceutical measures (vaccines, antibodies, ventilators, etc.) and nonpharmaceutical measures (wear masks, travel restrictions, school closing, cancel public events, stay at home requirements, etc.). Although pharmaceutical measures can target specific pathogens, nonpharmaceutical interventions affect a wide range of infectious diseases. Recent studies [8,9,10] have shown that the nonpharmaceutical interventions (NPIs) (lockdown, restriction on gathering, etc.) during the COVID-19 pandemic may reduce the prevalence of sexually transmitted diseases. Similar outcomes were also seen in Tuberculosis [11], seasonal influenza [12], and some other diseases [11, 13, 14]. 40 notifiable diseases need to be monitored, and some of them such as HBV [15], and Tuberculosis [16] had millions of new cases every year. We should pay attention to other infectious diseases in the context of COVID-19.
Some studies [11,12,13,14, 17] explored the impact of nonpharmaceutical interventions on respiratory infectious diseases during the COVID-19 pandemic. However, most studies only focused on the year 2020 when the COVID-19 outbroke. The ongoing NPIs persisted for years but changed with the level when the pandemic relaxed. The long-term ongoingnonpharmaceutical interventions for respiratory infectious diseases in China are still unclear, and there are still no studies based on national annual data. In this study, we aimed to explore the changes in seven respiratory infectious diseases before, during, and after COVID-19 in the Chinese mainland from 2010 to 2021.
The monthly case numbers of seven respiratory infectious diseases (Measles, Tuberculosis, Pertussis, Scarlet fever, Seasonal Influenza, Mumps, Rubella) were extracted from the website of the National Health Commission (http://www.nhc.gov.cn/jkj/s2907/new_list.shtml). All the data published by the Commission were originally from the China Information System for Disease Control and Prevention (CISDCP) [18, 19], which was a real-time disease-reporting system covering 40 notifiable infectious diseases (COVID-19 included in January 2020). The surveillance system was first established in 2004, covering 397 cities in 31 provinces in mainland China, covering a population of about 1.4 billion people. This system is based on the network and operates through administrative hierarchical responsibility and geographical management. The clinicians fill in the standard case report card for respiratory infectious diseases. Epidemic reports are time-sensitive, and respiratory infectious diseases should be reported within 24 h. All notifiable infectious diseases were timely reported to the local centers for disease control and prevention after diagnosis according to their standard criteria [20]. Seven respiratory infectious diseases without detailed information from the government’s website were included in our research. Demographic statistics data came from the website of the statistical yearbook of the National Bureau of Statistics (http://www.stats.gov.cn/tjsj/ndsj/). The study was approved by the institutional ethics review committee at Hangzhou Xixi Hospital (2022 Science Ethic No.36). Waiver of informed consent was granted by the institutional ethics review committee at Hangzhou Xixi Hospital (2022 Science Ethic No.36).
The confirmed Chinese COVID-19 cases in 2020 and 2021 came from the 2019 Novel Coronavirus COVID-19 (2019-nCoV) Data Repository provided by Johns Hopkins University [21]. The implementation of the main NPIs in China from 2020 to 2021 is illustrated in the supplementary Fig. 1. The indicators of government control measures were extracted from COVID-19 Government Response Tracker (GRT) [22]. Eight indicators were chosen from the GRT system, which were workplace closing, school closing, cancel public events, stay-at-home requirements, restrictions on gathering size, closed public transport, restrictions on internal movement, and international travel controls. The strictness of the nonpharmaceutical interventions increased with the score of indicators. The indicators are recorded on an ordinal scale that represents the level of strictness of the policy. Government coronavirus policies often vary by region within countries. Coding the most stringent government policy that is in place in a country/territory, as represented by the highest ordinal value. Sometimes the most stringent policy in a country/territory will only apply to a small part of the population. If the most stringent policy is only present in a limited geographic area or sector (e.g. perhaps only one province has implemented policies at a high level), the indicators use a binary flag variable to denote this limited scope. The detailed method of the NPIs can be found on the website (https://www.bsg.ox.ac.uk/research/research-projects/covid-19-government-response-tracker).
The pandemic phases were defined as Phase 1 (2010–2018, before COVID-19), Phase 2 (2019, pervious year of COVID-19), Phase 3 (2020, first year of COVID-19), and Phase 4 (2021, second year of COVID-19). Here we calculated the percentage change of (2010–2018)/2019 with the average yearly cases of 2010–2018 divided by the reported cases of the year 2019, 2020/2019 was the number of the year 2020 divided by the number of the year 2019, and so on 2021/2019 and 2021/2020.
ARIMA models were used to formulate the trend of respiratory diseases with the monthly data, and we used the forecast::auto.Arima() function in the R software to find a fitted model. Root mean square error (RMSE), mean absolute percentage error (MAPE), Akaike’s information criterion (AIC), and Bayesian information criterion (BIC) were used to evaluate the goodness-of-fit of constructed models. Ljung–The box test was used to check whether the residual of the model was a white noise (p > 0.05 for white noise). To estimate the benefits of NPIs against COVID-19 on respiratory diseases, we used the relative reduction as the indicator, and the calculation formula of relative reduction was: Relative reduction (%) = 100% × (number of expected cases – number of observed cases)/number of expected cases.
The daily national indicators of the eight COVID-19 control measures from the GRT system were newly calculated by the 31 provinces’ average score, and the monthly national indicators were the average of the daily data. The Pearson correlation analysis was conducted to measure the relationship between the monthly eight indicators and monthly COVID-19 cases and seven respiratory diseases. A two-sided P < 0.05 was considered statistically significant.
To adjust potential confounding factors of NPI, e.g., long-term disease trends, and indicators of government control measures, some multivariable generalized linear models (GLM) were constructed to explore the impact of NPIs on each respiratory disease. The pandemic phases were defined as Phase 1 (2010–2018), Phase 2 (2019), Phase 3 (2020), and Phase 4 (2021), and the reference period is Phase 2 (2019). X-13ARIMA-SEATS (signal extraction) method was used to obtain seasonality-removed monthly case numbers for each disease [13]. SEATS decomposes the time series into seasonal, trend, transitory, and irregular components, assigning deterministic effects to each component. A fundamental assumption made by SEATS is that the linearized time series \({y_t}\) (log of monthly case numbers in our analysis) follows the ARIMA model
\({y_t}\) is the time series, \(x_{t}^{'}\beta\) is the regression part with covariates \(xt\) , \(\alpha \text{t}\) is the white noise with mean 0 and variance σ,
B and \(B\text{s}\) : the non-seasonal and seasonal operators, B (\({y_t}\) )=\(yt - 1\) , \(B\text{s}\) (\({y_t}\) )=\(yt - 12\) ;
\(\AE\left(B\right)=1-AE1\;B^1-\dots\;-AE\;\rho B^\rho\) , reflects a non-seasonal autoregressive (AR) operator of order ρ;
\(\mathrm F\left({\mathrm B}_{\mathrm s}\right)=1-\;{\mathrm{AE}}_1\;{\mathram B}_{\mathrm s}^1 -\dots-\;\AE\;\mathrm\rho B_{\mathrm s}^\rho\) , reflects the seasonal AR operator of order ρ;
\(\mathbf{\left({1\mathrm-\mathrm B}\right)}^{\mathrm d}\mathbf{\left({1\mathrm-{\mathrm B}_{\mathrm s}} \right)}^{\mathrm D}\) , non-seasonal and seasonal operators of orders d and D;
\(\theta(B)=1-/AE_1\mathbf{\left(\mathrm B\right)}^1-\dots-/AE_q\left(B\right)^{\mathrm q}\) , reflects non-seasonal moving average (MA) order of q;
\(\Theta (B_\text{s})\) = 1-\(\Theta_1(B_\text{s}{)^1}\) -…-\(\Theta_\text{Q}(B_\text{s}{)^Q}\) , reflects seasonal MA order of Q.
The holiday effect of the Chinese New Year was adjusted by the “genhol” function in the R package “seasonal” (version 1.8.3). SEATS automatically detects the shifts in the mean level of the time series, which means it can partially account for the impact of NPIs during the COVID-19 pandemic when estimating seasonality. Two outputs were obtained from SEATS, the seasonality-removed monthly case numbers and the seasonal trend itself. Using the seasonality-removed monthly case numbers to construct GLM with two stages. In stage I, we fitted GLM with the quasi-Poisson method using the following factors: phase 1–4 indicators for the year 2010–2021, long-term trend, number of person-days (the number of days times population size) as an offset. In stage II, we extracted the residuals from the stage I model with one month lag as an independent variable to account for autocorrelation. The incidence rate ratios (IRR) estimated by the model of stage II reflect the effects of COVID-19 NPIs on the incidence of seven respiratory diseases in 2020 and 2021 [23]. In addition, we selected the pandemic year of 2020 and 2021 to construct a GLM, with eight factors extracted from the GRT system added to the model in stage I. Stage II also included the residuals from the stage I model with one month lag, and the IRR of 2021 compared with 2020 would reflect the effects of COVID-19 NPIs. A sensitivity analysis using the harmonic functions to adjust for seasonality (detailed in the Supplementary material) was conducted in this research. All statistical analyses were conducted in R software (version 4.0.5, R Development Core Team 2020). Two-sided P < 0.05 was considered statistically significant.
There were 25,980,811 incident cases included in our research, with a yearly average of 2,165,068 cases which was a huge burden on the public health of China. Compared with the year 2019, the percentage changes in 2020 and 2021 were all below 100% ranging from 3.81 to 84.71% (Table 1, Fig. 1). Furthermore, the percentage changes of 2020/2019 and 2021/2019 for Measles, Pertussis, Scarlet fever, Seasonal influenza, Mumps, and Rubella were all below 50%, indicating a more than 50% reduction of the six respiratory diseases during the COVID-19 era compared with the year 2019. Pertussis and Scarlet fever started to increase in 2021 compared with 2020, with a percentage change of 183.46 and 171.49%, but cases of year 2021 for the Measles, Tuberculosis, Seasonal influenza, Mumps, and Rubella remained lower than the reported cases of the year 2020.
Percentage change of seven respiratory diseases before and after COVID-19. Percentage change of (2010–2018)/2019 was calculated with the average yearly cases of 2010–2018 divided by the number of the year 2019, 2020/2019 was the number of the year 2020 divided by the number of the year 2019, and so on 2021/2019 and 2021/2020
The optimal models for the seven respiratory diseases were listed in Table 2. The MAPE showed a good fit of the models, and all the models passed the Ljung-Box test. The predicted data fitted well with the actual data from 2010 to 2019, but the predicted data was bigger than the actual number (Fig. 2) in 2020 and 2021 corresponding to the COVID-19. The trend of Mumps, Rubella, and Tuberculosis showed the same pace in 2020 and 2021, but Pertussis, Scarlet fever, and Seasonal influenza started to rise at the end of 2021. Tuberculosis has the smallest relative reduction, but Seasonal influenza and Rubella have the highest relative reduction. The detail of the relative reduction for the seven respiratory diseases can be seen in the Supplementary Table S1.
Autoregressive integrated moving average model fitting and prediction of the reported case numbers of seven respiratory diseases. A Measles, B Tuberculosis, C Pertussis, D Scarlet fever, E Seasonal influenza, F Mumps, G Rubella
The monthly number of COVID-19 cases was only negatively associated with Tuberculosis (r = − 0.57, P < 0.01) (Table 3). All the eight government control measures could affect the incidence of respiratory diseases. Close public transport was only negatively correlated with Scarlet fever (r = − 0.59, P < 0.01), and Stay at home was negatively correlated with Scarlet fever (r = − 0.51, P < 0.05) and Mumps (r = − 0.44, P < 0.05) (Table 3). School closing and Workplace closing were simultaneously negatively associated with Measles (r = − 0.50/− 0.52, P < 0.05/0.05), Scarlet fever (r = − 0.53/− 0.55, P < 0.05/0.01), and Mumps (r = − 0.61/− 0.59, P < 0.01/0.01), respectively. Except for the Scarlet fever, Restrictions on internal movement had a negative correlation with the other six respiratory diseases. In addition, Cancel public events, Restrictions on gatherings, and International travel controls were negatively correlated with 5 (Measles, Scarlet fever, Seasonal influenza, Mumps, and Rubella), 4 (Measles, Tuberculosis, Scarlet fever, and Mumps), and 4 (Tuberculosis, Scarlet fever, Seasonal influenza, and Rubella) respiratory diseases (Table 3), respectively.
All the seven respiratory diseases were significantly reduced during the COVID-19 pandemic in phase 3 (2020) and phase 4 (2021) compared with 2019, with significant estimated incidence rate ratios (IRRs) ranging from 0.06 to 0.85 (Table 4). For phase 1 (2010–2018), the significant IRRs of Measles and Tuberculosis were 4.69 (3.35–6.56) and 1.22 (1.16–1.28), but Pertussis, Scarlet fever, Seasonal influenza, and Rubella were below 1 with P-value < 0.001 (Table 4). The sensitivity analysis using harmonic functions showed qualitatively similar to the primary analysis (Supplementary Table S2).
The eight indicators from the GRT system were included to construct a model for the year 2020 and 2021, and the reference is the year 2020. Among the eight indicators from the GRT system, only Close public events, Stay at home, and Restrictions on Internal movement were statistically different between 2020 and 2021 (Fig. 3). In our primary univariate analysis of Model 1 (Table 5), the IRR was significantly different in Measles (0.82 (0.68–0.99)), Pertussis (3.16 (2.04–4.89)), Scarlet fever (2.47 (1.51–4.03)), and Seasonal influenza (3.4 (1.32–8.75)). However, this association disappeared after adjustment for eight indicators in Model 2 in multivariate analysis (Table 5).
Scores of eight COVID-19 control measures and trends of COVID-19 case numbers in 2020 and 2021. Grey dashed lines are not statistically significant between 2020 and 2021; Blue dashed lines are statistically significant between 2020 and 2021. A School Closing, B Workplace closing, C Cancel public events, D Restrictions on gatherings, E Close public transport, F Stay at home, G Restrictions on internal movement, H International travel controls, I COVID-19 cases
There were 25,980,811 incident cases included in our research, with a yearly average of 2,165,068 cases which was a huge burden on the public health of China. Among the 40 notifiable reported infectious diseases, seven respiratory diseases accounted for 31.03% of all the diseases from 2010 to 2021.With the outbreak of COVID-19, China has implemented a lot of personal protective measures such as hand washing, wearing masks, and social distance. Social measures such as workplace closing, school closing, canceling public events, stay-at-home requirements, restrictions on gathering size, closing public transport, restrictions on internal movement, and international travel controls, could reduce the prevalence of respiratory diseases.
Our study demonstrated the incidence of the seven respiratory diseases decreased rapidly during the COVID-19 era. Take Seasonal influenza as an example, it has 3,507,306 cases in 2019 and 986,543 cases in January 2020, but the remaining 2020 and 2021 were only 894,917. Similar results were also found in previous research [10, 11, 13] on China, and other countries such as Australia [24], America [25], and New Zealand [26]. We constructed the ARIMA model for the seven respiratory diseases, and the models fitted well in the year 2010–2019 but fitted badly in the year 2020–2021. The predicted incidence for the year 2020–2021 was higher than the actual data (Fig. 2). Tuberculosis has the smallest relative reduction, but Seasonal influenza and Rubella have the highest relative reduction.
Two reasons can be explained by the decline of respiratory diseases. Firstly, under strict control measures, the route of disease transmission has been broken, making it difficult for susceptible people to be exposed to pathogens. Chinese researchers [27] found travel out of Wuhan after the Chinese Lunar New Year averaged 6.7 million people in 2017 and 2018, but the travel ban prevented almost all of that movement in 2020. With strict NPIs, such as workplace closing, school closing, and public transport closing, there were hundreds of million people isolated at home without contact with the outside. Secondly, the NPIs to mitigate COVID-19 could affect the testing and treatment of respiratory diseases. We found the more stringent the control measures, the more declines in reported cases, especially for February 2020 with the highest scores of eight indicators and lowest incidence for the seven respiratory diseases. A study [28] showed that 26.9% of Chinese tuberculosis patients had postponed or missed their follow-up examinations due to travel restrictions and fear of COVID-19. In America, researchers [29] found a 61% decrease in the number of specimens submitted and a 98% decrease in influenza activity determined by the percentage of submitted specimens testing positive.
As the strictest NPIs implemented, China initiated a level-1 response to the COVID-19 pandemic, and the number of newly COVID-19 patients was decreasing quickly around the country [30]. With the decreasing COVID-19, all provinces downgraded public health response to level 2 or level 3, but stringent NPIs still remained in China, e.g., routine temperature monitoring, social distancing, and limiting businesses. When schools reopened on Sep 1, 2020, businesses and entertainment activities resumed nationwide marking the end of strict NPIs. Study [31] found that working resuming has little effect on the COVID-19 resurgence. We extracted eight indicators from the GRT system to quantify the effect of NPIs on respiratory infectious diseases. The correlation analysis showed all the eight control measures had negative associations with the seven diseases.
The IRR of the year 2020 and 2021 were all significantly below 1 compared with the year 2019, which suggested the prevalence of seven respiratory diseases reduced during the COVID-19 era compared with the year 2019 before the outbreak of COVID-19. Many studies have demonstrated the decreasing trend in the first year of COVID-19 [6, 11, 17, 26, 29, 32], but our study showed that the longer-term second year of COVID-19 was also decreasing. We then constructed a GLM with eight indicators for the year 2020 and 2021 corresponding to the COVID-19 pandemic and found IRR was not significant after adjusting for the eight control measures. Similar outcomes were also seen in other research, the incidence increased with the relaxation of NPIs. Wenping et al. showed the 2020–2021 influenza season did not occur, but circulations of the respiratory syncytial virus, parainfluenza, and seasonal coronavirus have returned since spring 2021 after the easing of NPIs [32]. Research conducted in Shanghai [33] found the positive rates of respiratory syncytial virus and enteric adenoviruses increased as the NPIs were relaxed in 2021. In our study, we did see a rising trend for the seven respiratory diseases at the end of 2021 when the NPIs relaxed in China (Fig. 1, Table 5), but the rising trend disappeared after adjusting for the eight indicators.
There are two main differences between our research and previous studies. Firstly, many studies [10, 12, 13, 17, 34] only evaluate infectious diseases in 2020, while our research has studied the data in 2021; secondly, methods of evaluating NPIs. Many studies [11, 13, 34] evaluated NPIs mainly by classifying NPIs at some large social points, while we evaluate NPIs by some quantitative indicators, which can more objectively reflect the impact of NPIs on diseases. Our research shows that the implementation of NPIs can effectively block the spread of respiratory infectious diseases. But changes in the reported cases of chronic respiratory infectious diseases (such as tuberculosis) may be more related to insufficient reporting than to NPI, and it is necessary to closely monitor the potential increase in disease progress and mortality due to delayed diagnosis and treatment during the pandemic [35]. The travel and assembly bans and other highly destructive NPIs cannot be used as long-term solutions, because they cause great harm to economic and social activities. Whether to restore the normal operation of the whole society or to maintain NPIs to stop the disease, many countries in the world have given different answers. It is hard to say that such a practice is necessarily correct, but combining less destructive NPI with effective vaccines and treatment schemes, such as social distancing and large indoor gatherings and wearing masks for public transport, may be a better solution.
Our study has some limitations. First, the monthly data we collected from the government website was originally from the China Information System for Disease Control and Prevention, which inevitably had a bias. Patients with respiratory diseases can’t be diagnosed by medical services which causes the missing reports, and thus the actual cases could be underestimated. Second, many variables could affect the prevalence of respiratory diseases, such as population vaccination, climate change, and virus variation, but we only included the eight indicators of NPIs. More variables should be included to specify the impact of NPIs in the future. Third, the monthly data was the national data, but not specific to provinces or cities, which may neglect the spatial heterogeneity of disease patterns. Finally, it seems almost impossible to independently assess the relationship between each NPIs and its outcome. One approach to consider would be to assess the impact in a bundled way like a sum. However, all the NPIs implemented in China represented different interventions, and the sum for the NPIs was too crude. Future research should find a better way to bundle the NPIs. In conclusion, our study demonstrated the incidence of the seven respiratory diseases decreased rapidly during the COVID-19 pandemic in 2020 and 2021. At the end of 2021, we did see a rising trend for the seven respiratory diseases compared to the year 2020 when the NPIs relaxed in China, but the rising trend was not significant after adjusting for the NPIs indicators. Our study showed that NPIs have an effect on respiratory diseases, but Relaxation of NPIs might lead to the resurgence of respiratory diseases.
The R script can be found online (https://osf.io/hvdjn/), and further inquiries can be directed to the corresponding authors. The data is taken from publicly available sources which can be found mainly on the following websites: 1. website of the National Health Commission (http://www.nhc.gov.cn/jkj/s2907/new_list.shtml); 2. website of University of Oxford. COVID-19 Government Response Tracker (https://www.bsg.ox.ac.uk/research/research-projects/covid-19-government-response-tracker).
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England). 2020;395(10223):497–506.
Li J, Gong X, Wang Z, Chen R, Li T, Zeng D, et al. Clinical features of familial clustering in patients infected with 2019 novel coronavirus in Wuhan, China. Virus research. 2020;286:198043.
Spina S, Marrazzo F, Migliari M, Stucchi R, Sforza A, Fumagalli R. The response of Milan's emergency medical system to the COVID-19 outbreak in Italy. Lancet (London, England). 2020;395(10227):e49–50.
Tsang HF, Chan LWC, Cho WCS, Yu ACS, Yim AKY, Chan AKC, et al. An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies. Expert Rev Anti-Infect Ther. 2021;19(7):877–88.
[ PMC free article ] [ PubMed ] Saalim K, Sakyi KS, Fatema Tuz Z, Morrison E, Owusu P, Dalglish SL, et al.Reported health and social consequences of the COVID-19 pandemic on vulnerable populations and implemented solutions in six West African countries: a media content analysis.PLoS One.2021;16(6):e0252890.
Bonnet E, Bodson O, Le Marcis F, Faye A, Sambieni NE, Fournet F, et al.The COVID-19 pandemic in francophone West Africa: from first cases to responses in seven countries.BMC Public Health.2021;21(1):1
Organization WH. WHO coronavirus (COVID-19) dashboard 2022. Available from: https://covid19.who.int/.
Latini A, Magri F, Donà MG, Giuliani M, Cristaudo A, Zaccarelli M. Is COVID-19 affecting the epidemiology of STIs? The experience of syphilis in Rome. Sex Transm Infect. 2021;97(1):78.
de Miguel BR, Trigo E, de la Calle-Prieto F, Arsuaga M, Díaz-Menéndez M. Social distancing to combat COVID-19 led to a marked decrease in food-borne infections and sexually transmitted diseases in Spain. J Travel Med. 2020:27(8):taaa134.
Yan X, Wang X, Zhang X, Wang L, Zhang B, Jia Z. The epidemic of sexually transmitted diseases under the influence of COVID-19 in China. Front Public Health. 2021;9:737817.
Chen B, Wang M, Huang X, Xie M, Pan L, Liu H, et al. Changes in incidence of notifiable infectious diseases in China under the prevention and control measures of COVID-19. Front Public Health. 2021;9:728768.
Feng L, Zhang T, Wang Q, Xie Y, Peng Z, Zheng J, et al. Impact of COVID-19 outbreaks and interventions on influenza in China and the United States. Nat Commun. 2021;12(1):3249.
Geng MJ, Zhang HY, Yu LJ, Lv CL, Wang T, Che TL, et al. Changes in notifiable infectious disease incidence in China during the COVID-19 pandemic. Nat Commun. 2021;12(1):6923.
Dadras O, Alinaghi SAS, Karimi A, MohsseniPour M, Barzegary A, Vahedi F, et al.Effects of COVID-19 prevention procedures on other common infections: a systematic review.Eur J Med Res.2021;26(1):6
Zhang M, Wu R, Xu H, Uhanova J, Gish R, Wen X, et al. Changing incidence of reported viral hepatitis in China from 2004 to 2016: an observational study. BMJ Open. 2019;9(8):e028248.
Zhang Q, Song W, Liu S, An Q, Tao N, Zhu X, et al. An ecological study of tuberculosis incidence in China, from 2002 to 2018. Front Public Health. 2021;9:766362.
Itaya T, Furuse Y, Jindai K. Does COVID-19 infection impact on the trend of seasonal influenza infection? 11 countries and regions, from 2014 to 2020. Int J Infect Dis. 2020;97:78–80.
Wang L, Wang Y, Jin S, Wu Z, Chin DP, Koplan JP, et al. Emergence and control of infectious diseases in China. Lancet (London, England). 2008;372(9649):1598–605.
Yang S, Wu J, Ding C, Cui Y, Zhou Y, Li Y, et al. Epidemiological features of and changes in incidence of infectious diseases in China in the first decade after the SARS outbreak: an observational trend study. Lancet Infect Dis. 2017;17(7):716–25.
Dong Y, Wang L, Burgner DP, Miller JE, Song Y, Ren X, et al. Infectious diseases in children and adolescents in China: analysis of national surveillance data from 2008 to 2017. BMJ (Clinical research ed). 2020;369:m1043.
Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533–4.
Hale T, Angrist N, Goldszmidt R, Kira B, Petherick A, Phillips T, et al. A global panel database of pandemic policies (Oxford COVID-19 government response tracker). Nat Hum Behav. 2021;5(4):529–38.
Imai C, Armstrong B, Chalabi Z, Mangtani P, Hashizume M. Time series regression model for infectious disease and weather. Environ Res. 2015;142:319–27.
Yeoh DK, Foley DA, Minney-Smith CA, Martin AC, Mace AO, Sikazwe CT, et al. Impact of coronavirus disease 2019 public health measures on detections of influenza and respiratory syncytial virus in children during the 2020 Australian winter. Clin Infect Dis. 2021;72(12):2199–202.
Auger KA, Shah SS, Richardson T, Hartley D, Hall M, Warniment A, et al. Association between statewide school closure and COVID-19 incidence and mortality in the US. Jama. 2020;324(9):859–70.
Huang QS, Wood T, Jelley L, Jennings T, Jefferies S, Daniells K, et al. Impact of the COVID-19 nonpharmaceutical interventions on influenza and other respiratory viral infections in New Zealand. medRxiv. 2020;2020.11.11.20228692.
Tian H, Liu Y, Li Y, Chieh-Hsi Wu, Bin Chen, Moritz UG Kraemer, et al.An investigation of transmission control measures during the first 50 days of the COVID-19 epidemic in China.Science (New York, NY).2020;368(6491):638–642.
Fei H, Yinyin X, Hui C, Ni W, Xin D, Wei C, et al. The impact of the COVID-19 epidemic. Lancet Regional Health Western Pacific. 2020;3:100032.
Olsen SJ, Azziz-Baumgartner E, Budd AP, Brammer L, Sullivan S, Pineda RF, et al. Decreased influenza activity during the COVID-19 pandemic-United States, Australia, Chile, and South Africa, 2020. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2020;20(12):3681–5.
Fu X, Ying Q, Zeng T, Long T, Wang Y. Simulating and forecasting the cumulative confirmed cases of SARS-CoV-2 in China by Boltzmann function-based regression analyses. J Infect. 2020;80(5):578–606.
Zhao K, Long C, Wang Y, Zeng T, Fu X. Negligible risk of the COVID-19 resurgence caused by work resuming in China (outside Hubei): a statistical probability study. J Public Health (Oxford, England). 2020;42(3):651–2.
Hu W, Fries AC, DeMarcus LS, Thervil JW, Kwaah B, Brown KN, et al. Circulating trends of influenza and other seasonal respiratory viruses among the US Department of defense personnel in the United States: impact of the COVID-19 pandemic. Int J Environ Res Public Health. 2022;19(10):5942.
Liu P, Xu M, Lu L, Ma A, Cao L, Su L, et al. The changing pattern of common respiratory and enteric viruses among outpatient children in Shanghai, China: two years of the COVID-19 pandemic. J Med Virol. 2022.
Xiao J, Dai J, Hu J, Liu T, Gong D, Li X, et al. Co-benefits of nonpharmaceutical intervention against COVID-19 on infectious diseases in China: a large population-based observational study. Lancet Regional Health Western Pacific. 2021;17:100282.
Hogan AB, Jewell BL, Sherrard-Smith E, Vesga JF, Watson OJ, Whittaker C, et al. Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study. Lancet Glob Health. 2020;8(9):e1132–e41.
We would like to thank all the clinical personnel for investigating and reporting the information about the infectious cases.
This research was funded by General projects of Hangzhou health science and technology plan in 2020 (A20200157), Hangzhou Science and Technology Bureau (2021WJCY185), Zhejiang Medical and Health Science and Technology Plan Project (2022KY1028), and Hangzhou Science and technology development plan (202004A20). The funders had no role in the study design, data collection, and analysis, decision to publish, or preparation of the manuscript.
Zhongbao Zuo and Chunli Yang contributed equally to this work and share the first authorship.
Department of Clinical Laboratory, Hangzhou Xixi Hospital, 2 Hengbu Road, Xihu District, Zhejiang, 310023, China
Zhongbao Zuo, Miaochan Wang, Jing Wu & Aifang Xu
Department of Clinical Laboratory, The 903rd Hospital of PLA, Zhejiang, 310013, China
Health Examination Center, Hangzhou Xixi Hospital, Zhejiang, 310023, China
Department of Obstetrics and Gynecology, Hangzhou Xixi Hospital, Zhejiang, 310023, China
Department of Hepatology, Hangzhou Xixi Hospital, Zhejiang, 310023, China
Yunhao Xun, Shourong Liu & Jinsong Huang
Science and Education Department, Hangzhou Xixi Hospital, Zhejiang, 310023, China
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
ZZ, AX, SL, and JH: design the study. CY, MW, and JW: collect data. ZZ and ZL: data analysis. ZZ and CT: write the manuscript. ZZ and YX: revise the manuscript. All authors contributed to the article and approved the submitted version.
The study was approved by the institutional ethics review committee at Hangzhou Xixi Hospital (2022 Science Ethic No.36). Waiver of informed consent was granted by the institutional ethics review committee at Hangzhou Xixi Hospital (2022 Science Ethic No.36). All methods were performed in accordance with the relevant guidelines and regulation.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Each month’s Relative reduction of seven respiratory diseases in 2020 and 2021. Supplementary Table S2. Sensitivity analysis for model-estimated incidence rate ratio (IRR) of seven Respiratory infectious diseases.
The epidemic process of COVID-19 and nonpharmaceutical interventions from 2020 to 2021 in China.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Zuo, Z., Yang, C., Ye, F. et al. Trends in respiratory diseases before and after the COVID-19 pandemic in China from 2010 to 2021. BMC Public Health 23, 217 (2023). https://doi.org/10.1186/s12889-023-15081-4
DOI: https://doi.org/10.1186/s12889-023-15081-4
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative
By using this website, you agree to our Terms and Conditions, California Privacy Statement, Privacy statement and Cookies policy. Manage cookies/Do not sell my data we use in the preference centre.
![Trends in respiratory diseases before and after the COVID-19 pandemic in China from 2010 to 2021 | BMC Public Health | Full Text](http://cdn.globalso.com/qomo-odm/Multifunctional-Wireless-Qpen-2.jpg)
Interactive Whiteboard Distributor © 2023 BioMed Central Ltd unless otherwise stated. Part of Springer Nature.